Drugs for Bile Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 8)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lanreotide |
Approved |
Phase 2 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
2 |
|
Esomeprazole |
Approved, Investigational, Vet_approved |
|
|
73590-58-6, 119141-88-7 |
9568614 4594 |
Synonyms:
( -)-Omeprazole
(−)-omeprazole
(-)-Omeprazole
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(S)-Omeprazole
(S)-omeprazole|Nexium®
2,3,5-Trimethylpyridine/Omeprazole
A02BC05
Alenia
Antra
Antra mups
AstraZeneca brand OF esomeprazole magnesium
Audazol
Aulcer
Axagon
Belmazol
Ceprandal
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
EMOZUL
Epirazole
Erbolin
Escz
Esofag
Esomeprazol
Esomeprazole
Ésoméprazole
Esomeprazole magnesium
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168/68|Losec®|Prilosec®
H-168/68
Indurgan
Inexium paranova
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
LOSEC MUPS
Lucen
Magnesium, omeprazole
Mepral
MEZZOPRAM
Miol
Miracid
Mopral
Morecon
Nexiam
Nexium
NEXIUM CONTROL
NEXIUM I.V.
Nexium IV
Nilsec
Nopramin
|
Nuclosina
Ocid
Olexin
Omapren
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole magnesium
Omeprazole pellets
Omeprazole S-form
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprol
OMERAN
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prilosec
Prilosec otc
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
Sanamidol
Secrepina
Sodium, omeprazole
Strontium, esomeprazole
Tedec ulceral
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
VENTRA
Victrix
ZANPROL
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
3 |
|
bilirubin |
|
|
|
635-65-4 |
5280352 |
Synonyms:
(4Z,15Z)-Bilirubin ixa
(Z,Z)-Bilirubin ixa
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionate
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid
1,10,19,22,23,24-Hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-biline-8,12-dipropionic acid
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoate
2,17-Diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoate
2,7,13,17-Tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
|
3-[2-[[3-(2-Carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate
3-[2-[[3-(2-Carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
8,12-Bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione
BILIRUBIN
Bilirubin IX alpha
Bilirubin ixalpha
Bilirubin IX-alpha
Bilirubin(Z,Z)
Bilirubin-ixalpha
Cholerythrin
Hematoidin
NSC-26685
|
|
4 |
|
Anti-Ulcer Agents |
|
|
|
|
|
5 |
|
Antacids |
|
|
|
|
|
6 |
|
Proton Pump Inhibitors |
|
|
|
|
|
7 |
|
Gastrointestinal Agents |
|
|
|
|
|
8 |
|
Bile Acids and Salts |
|
|
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy |
Withdrawn |
NCT00622804 |
Phase 3 |
|
2 |
Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy |
Unknown status |
NCT02054637 |
Phase 2 |
Lanreotide |
3 |
Prospective, Randomized, Controlled Trial of Omega Loop Gastric Bypass With and Without Anti-reflux Sutures - a Pilot Study |
Unknown status |
NCT03097887 |
|
|
4 |
The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy |
Unknown status |
NCT00441831 |
|
|
5 |
Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions: A Retrospective Cohort Study |
Completed |
NCT05131802 |
|
|
6 |
Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Multiple Center, Cross-sectional Study. |
Completed |
NCT03976739 |
|
|
7 |
The Role of Endoscopic Tri-Modal Imaging in Distinguishing Functional Dyspepsia From Reflux Disease |
Completed |
NCT02685150 |
|
Omeprazole |
8 |
Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index |
Recruiting |
NCT04845438 |
|
|
9 |
Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer: A Case-control Study |
Enrolling by invitation |
NCT04660058 |
|
|
10 |
Analysing the Link Between Tongue Signs and Bile Reflux by Artificial Intelligence |
Not yet recruiting |
NCT05369572 |
|
|
Cochrane evidence based reviews: bile reflux
|